South Korea Extends Bond Market Stabilization Measures Amid Rising Financial Risks 
Ireland Limits Planned Trade Ban on Israeli Settlements to Goods Only 
Oil Prices Slip in Asia as 2026 Supply Glut Fears and Russia-Ukraine Talks Weigh on Markets 
Russia Stocks End Flat as Energy and Retail Shares Show Mixed Performance 
Wall Street Futures Slip as Tech Stocks Struggle Ahead of Key US Economic Data 
Gold and Silver Prices Dip as Markets Await Key U.S. Economic Data 
Japan Business Sentiment Hits Four-Year High, Boosting Expectations of BOJ Rate Hike 
Dollar Struggles as Markets Eye Key Central Bank Decisions and Global Rate Outlooks 
Fed Near Neutral Signals Caution Ahead, Shifting Focus to Fixed Income in 2026 
Asian Technology and Chipmaking Stocks Slide as AI Spending Concerns Shake Markets 
S&P 500 Slides as AI Chip Stocks Tumble, Cooling Tech Rally 
Japan PMI Data Signals Manufacturing Stabilization as Services Continue to Drive Growth 
China’s November Economic Data Signals Slowing Industrial Output and Weak Consumer Demand 
U.S. Dollar Slips Near Two-Month Low as Markets Await Key Jobs Data and Central Bank Decisions 
China’s Small Bank Consolidation Struggles as Profits Fall and Risks Persist 
Bank of Japan Poised for Historic Rate Hike as Inflation Pressures Persist 
Eli Lilly to Introduce Mounjaro Weight-Loss Drug in Hong Kong by Year-End
Global pharmaceutical giant Eli Lilly is gearing up to launch its weight-loss drug, Mounjaro, in Hong Kong by the end of this year. According to a report from Bloomberg News, the company has received approval from Hong Kong's government to sell its tirzepatide injections under the Mounjaro brand.
Mounjaro for Weight Management and Diabetes
Eli Lilly's Mounjaro is designed for both long-term weight management and the treatment of type 2 diabetes. It will be available on the Kwikpen device, which allows for easy self-administration. The company aims to address the growing demand for effective weight-loss treatments while continuing to provide solutions for diabetes management.
Hong Kong Market Entry
Hong Kong marks a strategic entry point for Eli Lilly as it expands its global presence. With the approval of Mounjaro, the company is poised to offer a highly anticipated solution for individuals struggling with obesity and related health issues. The weight-loss sector has seen significant growth in recent years, and Mounjaro is expected to make a notable impact.
